Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biophytis ADR Representing 4000 Ord Shs BPTSY

Healthcare Biotechnology
Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The Company is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory... see more

Recent & Breaking News (OTCPK:BPTSY)

BIOPHYTIS - Results of the Combined General Meeting on May 10, 2021

GlobeNewswire May 11, 2021

Biophytis - Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders

GlobeNewswire April 30, 2021

Biophytis Receives Euro980,000 DeepTech Funding from BPI France for the development of Macuneos (BIO201) in Dry AMD

GlobeNewswire April 29, 2021

Biophytis - Convening of Another Combined General Meeting at a Later Date

GlobeNewswire April 27, 2021

Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021

GlobeNewswire April 26, 2021

BIOPHYTIS Identifies False Report Regarding COVA study

GlobeNewswire April 13, 2021

BIOPHYTIS Gives Updates on its Phase 2-3 COVA Study on COVID-19

GlobeNewswire March 22, 2021

Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis Against Negma Group Ltd

GlobeNewswire March 19, 2021

Biophytis' Combined Annual General Meeting Will Take Place on April 26, 2021 behind closed doors

GlobeNewswire March 10, 2021

Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial ("COVA Study") Following Regulatory Authorities Approvals in France and Belgium

GlobeNewswire February 17, 2021

Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market

GlobeNewswire February 15, 2021

Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext Growth

GlobeNewswire February 10, 2021

Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market

GlobeNewswire February 10, 2021